Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs Omzo

AM Rx
Graded #490

Lower grade

vs+4.300000000000004
Omzo
Graded #458

Higher grade

The verdict

Omzo takes it — 54.2/100 to 49.9/100.

Omzo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Omzo is a multi-pillar telehealth service (weight loss, women's hormone health, sexual health, hair, skin, daily health) offering clinician-guided compounded GLP-1 — semaglutide and tirzepatide — with free…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAM Rx +6
51
45
Dose & formulationAM Rx +25
65
40
Clinical oversightOmzo +35
41
76
Labs & monitoringOmzo +3
49
52
FulfillmentOmzo +5
58
63
Contract termsOmzo +35
20
55
AM Rx · left barOmzo · right bar

The numbers

MetricAM RxOmzo
WeighScore49.9/10054.2/100
GradeCC
Scorecard rank#490#458
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #490 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Omzo

Graded #458 · C

Strengths

  • Compounded GLP-1 (semaglutide and tirzepatide) with clinician guidance
  • Free, discreet delivery on all treatments
  • FSA/HSA eligible
  • Multi-pillar: also women's hormone, sexual health, hair, skin, and daily health

Where it loses points

  • Pricing not published on the site — shown only after the intake quiz
  • Compounding pharmacy partner not named (states only 'independent state-licensed')
  • States of operation not published
  • Not LegitScript-certified (no certification displayed)
  • Legal entity not named; governing law given only as 'the state in which Omzo operates'

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard